Table 1. Clinical trials that target IL-33/ST-2.
| Study title | Reference | Identifier | Stage* | Drug | Disease | Status |
|---|---|---|---|---|---|---|
| A first-in-human, double blind, single dose study in healthy subjects and subjects with mild atopic asthma | (154) | NCT01928368 | I | Astegolimab | Asthma | Completed |
| A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 282 in healthy subjects and subjects with chronic rhinosinusitis with nasal polyps | (155) | NCT02170337 | I | Astegolimab | CRS with NP | Completed |
| A study to assess the efficacy and safety of MSTT1041A in participants with uncontrolled severe asthma | (156) | NCT02918019 | II | Astegolimab | Asthma | Completed |
| A study to assess the efficacy and safety of MSTT1041A in participants with moderate to severe atopic dermatitis | (157) | NCT03747575 | II | Astegolimab | AD | Completed |
| Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) | (158) | NCT03615040 | II | Astegolimab | COPD | Completed |
| A study to evaluate the efficacy and safety of astegolimab in participants with chronic obstructive pulmonary disease | (159) | NCT05037929 | II | Astegolimab | COPD | Recruiting |
| A study investigating the efficacy, safety, and PK profile of ANB020 administered to adult subjects with moderate-to-severe AD (ATLAS) | (160) | NCT03533751 | II | Etokimab | AD | Recruiting |
| Proof of concept study to investigate ANB020 activity in adult patients with severe eosinophilic asthma | (161) | NCT03469934 | II | Etokimab | Asthma | Completed |
| Etokimab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) | (162) | NCT03614923 | II | Etokimab | CRS with NP | Completed |
| Placebo-controlled study to investigate ANB020 activity in adult patients with peanut allergy | (163) | NCT02920021 | II | Etokimab | Peanut allergy | Completed |
| A study to evaluate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Melrilimab (GSK3772847) in healthy participants | (164) | NCT04366349 | I | GSK3772847 | Healthy/asthma | Completed |
| Efficacy and safety study of GSK3772847 in subjects with moderately severe asthma | (165) | NCT03207243 | II | GSK3772847 | Asthma | Completed |
| Study of REGN3500 and dupilumab in patients with asthma | (166) | NCT03112577 | I | Itepekimab | Asthma | Completed |
| Study of safety, tolerability, and pharmacokinetics of multiple ascending doses of REGN3500 in adults with moderate asthma | (167) | NCT02999711 | I | Itepekimab | Asthma | Completed |
| Evaluation of SAR440340 and as combination therapy with dupilumab in moderate-to-severe asthma participants | (168) | NCT03387852 | II | Itepekimab | Asthma | Completed |
| Efficacy, safety, and pharmacokinetic profiles of REGN3500 administered to adult patients with moderate-to-severe atopic dermatitis | (169) | NCT03738423 | II | Itepekimab | AD | Completed |
| Efficacy and safety of REGN3500 monotherapy and combination of REGN3500 plus dupilumab in adult patients with moderate-to-severe atopic dermatitis | (170) | NCT03736967 | II | Itepekimab | AD | Terminated (Lack of efficacy) |
| Proof-of-concept study to assess the efficacy, safety and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) | (171) | NCT03546907 | II | Itepekimab | COPD | Completed |
| Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/Itepekimab in chronic obstructive pulmonary disease (COPD) (AERIFY-1,2) | (172,173) | NCT04701983 | III | Itepekimab | COPD | Recruiting |
| NCT04751487 | ||||||
| Safety and tolerability of MEDI3506 in healthy participants, in participants with COPD and healthy Japanese participants | (174) | NCT03096795 | I | MEDI3506 | Healthy/COPD | Completed |
| Study to assess the efficacy and safety of MEDI3506 in adults with uncontrolled moderate-to-severe asthma (FRONTIER-3) | (175) | NCT04570657 | II | MEDI3506 | Asthma | Recruiting |
| Efficacy and safety of MEDI3506 in adult subjects with atopic dermatitis | (176) | NCT04212169 | II | MEDI3506 | AD | Recruiting |
| A phase II, randomized, double-blind, placebo-controlled study to assess MEDI3506 in participants with COPD and chronic bronchitis (FRONTIER-4) | (177) | NCT04631016 | II | MEDI3506 | COPD/chronic bronchitis | Recruiting |
NP, nasal polyp.
*Stage I, II, and III represent phase 1, phase 2, and phase 3 respectively.